title: Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial.
authors.forename: Christopher
authors.initials: C
authors.lastname: Horvath
authors.forename: Laura
authors.initials: L
authors.lastname: Andrews
authors.forename: Andreas
authors.initials: A
authors.lastname: Baumann
authors.forename: Lauren
authors.initials: L
authors.lastname: Black
authors.forename: Diann
authors.initials: D
authors.lastname: Blanset
authors.forename: Joy
authors.initials: J
authors.lastname: Cavagnaro
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Hastings
authors.forename: David L
authors.initials: DL
authors.lastname: Hutto
authors.forename: Timothy K
authors.initials: TK
authors.lastname: MacLachlan
authors.forename: Mark
authors.initials: M
authors.lastname: Milton
authors.forename: Theresa
authors.initials: T
authors.lastname: Reynolds
authors.forename: Stan
authors.initials: S
authors.lastname: Roberts
authors.forename: Mark
authors.initials: M
authors.lastname: Rogge
authors.forename: Jennifer
authors.initials: J
authors.lastname: Sims
authors.forename: George
authors.initials: G
authors.lastname: Treacy
authors.forename: Garvin
authors.initials: G
authors.lastname: Warner
authors.forename: James D
authors.initials: JD
authors.lastname: Green
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized